Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
View/ Open
Date
2018-07-03ICR Author
Author
Gleeson, M
Peckitt, C
Cunningham, D
Gibb, A
Hawkes, EA
Back, M
Yasar, B
Foley, K
Lee, R
Dash, J
Johnson, H
O'Hara, C
Wotherspoon, A
Attygalle, A
Menasce, L
Shenjere, P
Potter, M
Ethell, ME
Dearden, C
Radford, J
Chau, I
Linton, K
Type
Journal Article
Metadata
Show full item recordAbstract
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
Collections
Subject
Humans
Lymphoma, T-Cell, Peripheral
Neoplasm Metastasis
Recurrence
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Staging
Prognosis
Treatment Outcome
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation
Survival Analysis
Follow-Up Studies
Adolescent
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Young Adult
Consolidation Chemotherapy
Induction Chemotherapy
Biomarkers
United Kingdom
Research team
Medicine (RMH Smith Cunningham)
Language
eng
License start date
2018-07
Citation
Leukemia & lymphoma, 2018, 59 (7), pp. 1586 - 1595
Publisher
TAYLOR & FRANCIS LTD